Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Follow-up from a Phase 1 study of a messenger RNA Covid-19 vaccine shows levels of binding and neutralising antibodies declined over time in 34 adults who received two 100mcg doses, but remained elevated in all participants 3 months after the booster dose.
Source:
New England Journal of Medicine
SPS commentary:
An ongoing Phase III study of this vaccine recently reported a 94.5% efficacy rate in an interim analysis. Based on this, the European CHMP initiated a rolling review in November.